TMCnet News

Global Actinic (Solar) Keratosis Pipeline Review 2016: Therapeutics Under Development by Companies & Universities - Research and Markets
[October 21, 2016]

Global Actinic (Solar) Keratosis Pipeline Review 2016: Therapeutics Under Development by Companies & Universities - Research and Markets


Research and Markets has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H2 2016" report to their offering.

'Actinic (Solar) Keratosis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies Universities.

'Actinic (Solar) Keratosis - Pipeline Review, H2 2016'; Actinic (Solar) Keratosis pipeline therapeutics constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes.

Actinic (Solar) Keratosis An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors includeage, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.



It also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Key Topics Covered:


  1. Introduction
  2. Actinic (Solar) Keratosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Actinic (Solar) Keratosis - Overview
  5. Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis
  6. Actinic (Solar) Keratosis - Therapeutics under Development by Companies
  7. Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes
  8. Actinic (Solar) Keratosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Actinic (Solar) Keratosis - Products under Development by Companies
  13. Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes
  14. Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
  • 3M (News - Alert) Drug Delivery Systems
  • Athenex, Inc.
  • Digna Biotech, S.L.
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Galderma S.A.
  • Laboratories Ojer Pharma S.L.
  • LEO Pharma A/S
  • Novartis AG
  • Oncology Research International Limited
  • Promius Pharma, LLC
  • Spherium Biomed S.L.
  • Valeant Pharmaceuticals International, Inc.
  • Vectura Group Plc

For more information about this report visit http://www.researchandmarkets.com/research/t6xnnm/actinic_solar


[ Back To TMCnet.com's Homepage ]